Accuray (ARAY) Registration Filing summary
Event summary combining transcript, slides, and related documents.
Registration Filing summary
17 Feb, 2026Company overview and business model
Develops, manufactures, sells, and supports radiation therapy solutions for complex and common cases, aiming for precision and reduced treatment times.
Key technologies include CyberKnife and TomoTherapy platforms, with applications in SRS, SBRT, IMRT, IGRT, and ART.
Offers services such as post-contract support, installation, training, and professional services.
Incorporated in California in 1990, reincorporated in Delaware in 2007, with principal offices in Madison, WI, and Santa Clara, CA.
Use of proceeds and capital allocation
Will not receive proceeds from the resale of shares by selling stockholders.
Will receive proceeds only from cash exercise of warrants, intended for general corporate purposes.
Risk factors and disclosures
Investment involves a high degree of risk, with risks detailed in incorporated annual and quarterly reports.
Risks include potential adverse impacts on business, results, and stock price.
Latest events from Accuray
- Stockholders to vote on $55M recapitalization, share increase, and reverse split to support transformation.ARAY
Proxy filing - Registration enables resale of 6.8M shares from warrants linked to recent financing.ARAY
Registration filing - Q3 FY26 revenue fell 7% and guidance was withdrawn amid geopolitical and macro headwinds.ARAY
Q3 2026 - Revenue and margin guidance cut as China headwinds, tariffs, and financing changes weigh.ARAY
Q2 2026 - FY2025 guidance raised as China growth and service gains offset margin and revenue declines.ARAY
Q1 2025 - Record Q4 revenue and shipments drive strong FY25 outlook and international expansion.ARAY
Q4 2024 - Growth driven by innovation, emerging markets, and margin expansion, with U.S. recovery expected.ARAY
Jefferies Global Healthcare Conference - Q3 FY25 revenue up 12%, net loss narrowed, but guidance cut on tariffs; EBITDA improved.ARAY
Q3 2025 - Q2 revenue up 8% to $116.2M, net income $2.5M, margin 36.1%, guidance raised.ARAY
Q2 2025